VIVEbiotech is also collaborating with a range of different suppliers to make its operations as efficient as possible.
Part B of the LIGHTHOUSE study will enroll adults and children. DURHAM, N.C., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused ...
National Resilience acquired the Triangle office in 2021. Since then, funding for gene therapy solutions has fallen.
A Rajya Sabha MP urges the health minister to enable local production of Risdiplam, a vital drug for spinal muscular atrophy, ...
CDMO National Resilience plots 120 layoffs at former bluebird bio facility in Research Triangle Park
Following a fresh round of job cuts in December, CDMO National Resilience is carrying its downsizing efforts into 2025. | ...
The securities described above are being offered by uniQure pursuant to its automatically effective shelf registration statement on Form S-3 (File No. 333-284168) filed with the U.S. Securities ...
Zacks.com on MSN13h
SLDB Stock Up as FDA Clears IND for SGT-212 in Friedreich's AtaxiaSolid Biosciences Inc. SLDB announced that the FDA has cleared its investigational new drug (IND) application to begin ...
Institutional investors interested in meeting with management during the conference may reach out to their J.P. Morgan representatives. About Solid Biosciences Solid Biosciences is a precision genetic ...
GlobalData on MSN18h
BIAL’s first subject completes full dose regimen in Parkinson’s treatment trialBIAL has completed the full dose regimen for the first subject in the Phase II ACTIVATE trial of BIA 28-6156, for Parkinson's treatment.
National Resilience is laying off 120 staffers from its gene therapy facility in North Carolina, only a month after the San ...
Clinical Trial Application for global Phase 3 trials with nizubaglustat in GM1/GM2 gangliosidoses and Niemann-Pick Disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback